Unknown

Dataset Information

0

Development of Phenyl-substituted Isoindolinone- and Benzimidazole-type Cereblon Ligands for Targeted Protein Degradation.


ABSTRACT: Thalidomide, pomalidomide and lenalidomide, collectively referred to as immunomodulatory imide drugs (IMiDs), are frequently employed in proteolysis-targeting chimeras (PROTACs) as cereblon (CRBN) E3 ligase-recruiting ligands. However, their molecular glue properties that co-opt the CRL4CRBN to degrade its non-natural substrates may lead to undesired off-target effects for the IMiD-based PROTAC degraders. Herein, we reported a small library of potent and cell-permeable CRBN ligands, which exert high selectivity over the well-known CRBN neo-substrates of IMiDs by structure-based design. They were further utilized to construct bromodomain-containing protein 4 (BRD4) degraders, which successfully depleted BRD4 in the tested cells. Overall, we reported a series of functionalized CRBN recruiters that circumvent the promiscuity from traditional IMiDs, and this study is informative to the development of selective CRBN-recruiting PROTACs for many other therapeutic targets.

SUBMITTER: Nie X 

PROVIDER: S-EPMC10922875 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Development of Phenyl-substituted Isoindolinone- and Benzimidazole-type Cereblon Ligands for Targeted Protein Degradation.

Nie Xueqing X   Zhao Yu Y   Tang Hua H   Zhang Zhongrui Z   Liao Junzhuo J   Almodovar-Rivera Chelsi M CM   Sundaresan Ramya R   Xie Haibo H   Guo Le L   Wang Bo B   Guan Hongqing H   Xing Yongna Y   Tang Weiping W  

Chembiochem : a European journal of chemical biology 20240115 4


Thalidomide, pomalidomide and lenalidomide, collectively referred to as immunomodulatory imide drugs (IMiDs), are frequently employed in proteolysis-targeting chimeras (PROTACs) as cereblon (CRBN) E3 ligase-recruiting ligands. However, their molecular glue properties that co-opt the CRL4<sup>CRBN</sup> to degrade its non-natural substrates may lead to undesired off-target effects for the IMiD-based PROTAC degraders. Herein, we reported a small library of potent and cell-permeable CRBN ligands, w  ...[more]

Similar Datasets

| S-EPMC12136240 | biostudies-literature
| S-EPMC8591746 | biostudies-literature
| S-EPMC10467047 | biostudies-literature
| S-EPMC2968276 | biostudies-literature
| S-EPMC9923830 | biostudies-literature
| S-EPMC7290497 | biostudies-literature
| S-EPMC8648984 | biostudies-literature
| S-EPMC3588497 | biostudies-literature
| S-EPMC12169847 | biostudies-literature